• SIGN IN
  • GET HELP
  •  

    Webinar Details


    Event Type

    Live Online

    Date

    Thursday, August 1, 2019

    Time

    9:00 PM - 10:00 PM ET

    Location

    PharmCon Webinar Studio (freeCE.com)

    Credits

    1 Contact Hour(s)

    Target Audience

    Pharmacist, Nurse

    Cost

    $30.00

    • Overview

      Direct oral anticoagulants (DOACs) are recognized by guidelines as first-line options for the treatment of venous thromboembolism and prevention of stroke and systemic embolism in nonvalular atrial fibrillation. Now that multiple DOACs have been FDA approved for these indications, and their use is wide-spread, it is challenging to ensure patient safety as each agent has slightly different pharmacokinetic considerations with its use. This program will address safety and efficacy with each agent, initial recommendations for dosing and adjustments based on renal considerations, drug interactions, and age and weight. Common risk factors for bleeding will be identified as well as options in support of the management of bleeding, if it should occur, are proposed.

      Rating

         4.75  out of 5


      Handouts

      Slide Document 18046L01_4pp(001).pdf
      Slide Document 18046L01_2pp(001).pdf





      Financial Support By

      PharmCon
    • Pharmacist

      Differentiate among the pharmacotherapeutic options available for the treatment of non-valvular atrial fibrillation and venous thromboembolism
      Apply knowledge of clinical trial data and guidelines in order to determine the most appropriate anticoagulant for individualized patients
      Based on risks for bleeding and other risk characteristics, recommend appropriate modifications and dose adjustments of direct oral anticoagulants

      Nurse

      Differentiate among the pharmacotherapeutic options available for the treatment of non-valvular atrial fibrillation and venous thromboembolism
      Apply knowledge of clinical trial data and guidelines in order to determine the most appropriate anticoagulant for individualized patients
      Based on risks for bleeding and other risk characteristics, recommend appropriate modifications and dose adjustments of direct oral anticoagulants
    • Repeat Presentation

      This presentation was last given on 9/18/2019 10:30 AM

      Future Airings

      Date Time
      Wednesday, September 18, 2019 10:30 AM View

    • Activity Type

      Knowledge

      CE Broker

      20-638110

      Universal Activity Number

      Pharmacist 0798-0000-18-046-L01-P

      Nurse 0798-0000-18-046-L01-P

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, attendees must answer poll questions and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.


    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).




    Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.